NCT02613507CompletedPhase 3
Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer
An Open-label Randomized Multinational Phase 3 Trial of Nivolumab Versus Docetaxel in Previously Treated Subjects With Advanced or Metastatic Non-small Cell Lung Cancer (CheckMate 078: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 078)
Source: ClinicalTrials.gov · Last updated 19 Nov 2024
Brief summary (registry, in English)
The purpose of this study is to determine whether Nivolumab improves life expectancy compared to Docetaxel in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who have failed prior platinum-based doublet chemotherapy.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 504 (actual)
- First submitted
- 22 Nov 2015
- Start date
- 11 Dec 2015
- Primary completion date
- 15 Sept 2017
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Lung cancer
- NCT number
- NCT02613507
- EudraCT number
- 2015-001893-16
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 504
- From 11 Dec 2015 to the primary completion date, 15 Sept 2017
- 33 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior treatment with Docetaxel
- Prior treatment with ipilimumab or any drug targeting T-Cell costimulation or checkpoint pathways
Other illness
- History of Carcinomatous meningitis
- History of auto immune diseases
Other
- Active Central nervous system (CNS) metastases
Who the study is looking for
- Disease progression experienced during or after one prior platinum containing doublet chemotherapy
- Stage IIIb/IV or recurrent disease
- Male and Female ≥ 18 years of age
- Measurable disease per RECIST 1.1
- Performance Status ≤ 1
Criteria the registry did not label
- For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (33)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.